

Financial news for FLXN dated on 2020-05-27: Guggenheim Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces Price Target of \$20

Financial news for FLXN dated on 2020-05-21: Flexion Therapeutics Prices ~9.23M Shares At \$9.75/Share

Financial news for FLXN dated on 2020-05-20: Flexion Therapeutics Announces A \$75M Common Stock Offering

Financial news for FLXN dated on 2020-05-19: Flexion Therapeutics Inc Says Continues To Expect To Experience A Material Decline In Revenues For Remainder Of 2020, And Possibly Longer

Financial news for FLXN dated on 2020-05-08: Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to \$20

Financial news for FLXN dated on 2020-05-08: RBC Capital Maintains Outperform on Flexion Therapeutics, Lowers Price Target to \$18

Financial news for FLXN dated on 2020-05-07: Flexion Therapeutics Q1 EPS \$(0.950) Beats \$(0.990) Estimate, Sales \$20.127M Beat \$19.800M Estimate

Financial news for FLXN dated on 2020-05-01: Flexion Therapeutics Highlights Publication Of New Abstract Accepted At Osteoarthritis Research Society International OARSI 2020

Financial news for FLXN dated on 2020-04-30: Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to \$30

Financial news for FLXN dated on 2020-04-27: Raymond James Maintains Strong Buy on Flexion Therapeutics, Lowers Price Target to \$20

Financial news for FLXN dated on 2020-04-27: Flexion Therapeutics Announces Positive Preclinical Data Supporting Development Of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate For Post-Pain

Financial news for FLXN dated on 2020-04-02: Benchmark Maintains Buy on Flexion Therapeutics, Lowers Price Target to \$17

Financial news for FLXN dated on 2020-04-01: Flexion Therapeutics Announces ZILRETTA License Agreement; Co. To Receive Upfront Payment Of \$10M, Up To \$32.5M In Milestones

Financial news for FLXN dated on 2020-01-09: Flexion Therapeutics Sees Prelim. Q4 Sales \$23.7M vs \$24.15M Est., Prelim. FY19 Sales \$73M vs \$73.43M Est.; Sees FY20 Product Revenues \$120M-\$135M

Financial news for FLXN dated on 2019-12-27: Needham Maintains Buy, \$36 Target On Flexion Therapeutics Notes 'Overall, we believe FLXN achieved its key goal of removing the LOU, which was a source of confusion for many physicians, and is now in a position to better promote Zilretta usage'

Financial news for FLXN dated on 2019-12-27: Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB

Financial news for FLXN dated on 2019-12-27: Raymond James Maintains Strong Buy on Flexion Therapeutics, Raises Price Target to \$28

Financial news for FLXN dated on 2019-12-26: Flexion Therapeutics shares are trading higher after the company announced FDA approval of sNDA to revise ZILRETTA product label.

Financial news for FLXN dated on 2019-12-26: Flexion Reports FDA Approval Of Supplemental New Drug Application To Revise ZILRETTA Product Label

Financial news for FLXN dated on 2019-12-17: Flexion Therapeutics Enrolls First Patients In Phase 2 Trial Of ZILRETTA In OA Of The Shoulder And Adhesive Capsulitis

Financial news for FLXN dated on 2019-12-05: Craig-Hallum Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces \$24 Price Target

Financial news for FLXN dated on 2019-11-25: BTIG Research Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces \$27 Price Target

Financial news for FLXN dated on 2019-11-11: Flexion Therapeutics Presents ZILRETTA Efficacy Data at the AAHKS and ACR Annual Meetings

Financial news for FLXN dated on 2019-11-07: Flexion Therapeutics Q3 EPS \$(1) Misses \$(0.96) Estimate, Sales \$21.786M Beat \$19.01M Estimate

Financial news for FLXN dated on 2019-10-31: Flexion Therapeutics Announces FDA Clearance Of Investigational New Drug Application For FX201 Gene Therapy Candidate For The Treatment Of Osteoarthritis

Financial news for FLXN dated on 2019-10-14: Flexion Therapeutics Notified by the FDA That it Needs More Time to Review the Supplemental New Drug Application for ZILRETTA

Financial news for FLXN dated on 2019-09-27: Flexion Therapeutics Names CEO Mike Clayman Chair

Financial news for FLXN dated on 2019-09-09: Flexion Therapeutics And Xenon Pharmaceuticals Announce Flexion's Acquisition Of An Investigational Nav1.7 Inhibitor For The Treatment Of Post-Operative Pain; Xenon Received \$3M Upfront And Is Eligible For Additional Milestones

Financial news for FLXN dated on 2019-08-06: Flexion Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for FLXN dated on 2019-08-06: Flexion Therapeutics Q2 EPS \$(0.96) Beats \$(1.05) Estimate, Sales \$16.953M Beat \$14.7M Estimate

Financial news for FLXN dated on 2019-07-15: Flexion Therapeutics Highlights Presentation Of New Data Evaluating Repeat Administration Of ZILRETTA In Patients With Advanced Knee OA

Financial news for FLXN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for FLXN dated on 2019-06-05: Flexion Therapeutics Announces Issuance Of New US Patent Covering FX201 A Gene Therapy Product Candidate For The Treatment Of Osteoarthritis

Financial news for FLXN dated on 2019-05-10: Flexion Therapeutics shares are trading higher after the company announced a pooled analysis of data from three Phase 2/3 clinical trials of medications with ZILRETTA were published in "Pain and Therapy."

Financial news for FLXN dated on 2019-05-10: Flexion Therapeutics Highlights Publication Of Pooled Analysis Of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA In 'Pain And Therapy'

Financial news for FLXN dated on 2019-05-09: Benchmark Upgrades Flexion Therapeutics, Inc. - Common Stock to Buy

Financial news for FLXN dated on 2019-05-08: Flexion Therapeutics Q1 EPS \$(1.09) Misses \$(1.08) Estimate, Sales \$10.564M Miss \$11.16M Estimate

Financial news for FLXN dated on 2019-04-24: Flexion Therapeutics Highlights Publication Of Analysis Of Patients With Unilateral Knee OA From Pivotal Trial Of ZILRETTA

Financial news for FLXN dated on 2019-04-02: Flexion Therapeutics Highlights Publication Of Independent Data Review Of ZILRETTA In The Journal Drugs

Financial news for FLXN dated on 2019-02-28: Flexion Therapeutics Q4 Sales \$9.5M Beat \$9.38M Estimate

Financial news for FLXN dated on 2019-02-21: Flexion Reports New In Vitro Data Showing Protective Effects Of Triamcinolone Acetonide On Cartilage

Financial news for FLXN dated on 2019-02-11: Flexion Therapeutics Highlights Publication Of Data from Repeat Administration Trial of ZILRETTA(r) in Rheumatology and Therapy In 'Rheumatology And Therapy'

Financial news for FLXN dated on 2019-01-04: Benchmark Downgrades Flexion Therapeutics to Hold

Financial news for FLXN dated on 2019-01-03: Flexion Therapeutics shares are trading lower after the company missed Q4 EPS and revenue estimates.

Financial news for FLXN dated on 2019-01-03: Flexion Sees FY19 Product Sales \$65M-\$80M

Financial news for FLXN dated on 2019-01-03: Flexion Sees Q4 Sales ~\$9.5M vs \$10.25M Estimate; FY18 Sales ~\$22.5M vs \$23.16M Est.

Financial news for FLXN dated on 2019-01-02: Flexion Reports Enrollment Of First Patient In Phase 3 Trial OF ZILRETTA In Hip Osteoarthritis, Offers Results From SHIP

Study

Financial news for FLXN dated on 2018-12-17: Flexion Therapeutics Submits Supplemental New Drug Application For ZILRETTA

Financial news for FLXN dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for FLXN dated on 2018-11-07: Flexion Therapeutics Q3 EPS \$(1.15) Beats \$(1.21) Estimate, Sales \$6.99M Beat \$6.75M Estimate

Financial news for FLXN dated on 2018-11-05: Flexion Therapeutics Announces the Product Specific Medicare & Medicaid Code for ZILRETTA Will Switch From Q to J

Financial news for FLXN dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for FLXN dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for FLXN dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for FLXN dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for FLXN dated on 2018-09-27: Stocks Which Set New 52-Week Low Yesterday, September 26th

Financial news for FLXN dated on 2018-09-26: Stocks Which Set New 52-Week Low Yesterday, September 25th

Financial news for FLXN dated on 2018-09-25: Stocks Which Set New 52-Week Low Yesterday, September 24th

Financial news for FLXN dated on 2018-09-24: Stocks Which Set New 52-Week Low Friday, September 21st

Financial news for FLXN dated on 2018-09-21: Stocks Which Set New 52-Week Low Yesterday, September 20th

Financial news for FLXN dated on 2018-09-10: Flexion Says Phase 2 Data Evaluating Zilretta Showed Lower Blood Glucose Levels Following Zilretta Injection Compared To TAcS Injeciton

Financial news for FLXN dated on 2018-08-07: Flexion Therapeutics Q2 EPS \$(1.16) Beats \$(1.23) Estimate, Sales \$3.8M Miss \$4.26M Estimate

Financial news for FLXN dated on 2018-06-28: Benchmark Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces \$39 Price Target

Financial news for FLXN dated on 2018-05-08: Flexion Therapeutics Q1 EPS \$(1.10) Beats \$(1.33) Estimate, Sales \$2.19M Miss \$2.46M Estimate

Financial news for FLXN dated on 2018-05-07: Flexion Therapeutics Names David Arkowitz CFO

Financial news for FLXN dated on 2018-05-04: Flexion Therapeutics Reports CMS Recommends ZILRETTA For Unique J Code

Financial news for FLXN dated on 2018-04-26: Flexion Therapeutics Says Avg. Time To Administer The 2nd Administration Of ZILRETTA Was 16.6 Weeks, 74% Of Patients Received This Between Weeks 16 And 24; Co. Reports Magnitude And Duration Of Pain Relief From The Injection Is In Line With Phase 3 Trial

Financial news for FLXN dated on 2018-04-18: Flexion Therapeutics Announces Pivotal Phase 3 ZILRETTA Study Results Published In Jounral of Bone and Joint Surgery

Financial news for FLXN dated on 2018-03-08: Flexion Therapeutics Reports FY17 EPS \$(4.16) vs \$(3.81) Est., Sales \$355K vs \$580K Est.

Financial news for FLXN dated on 2018-02-01: Berenberg Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces \$42.00 Price Target

Financial news for FLXN dated on 2018-01-25: Earlier 13G/A Filing Shows BlackRock Reporting 7.1% Stake In Flexion Therapeutics

Financial news for FLXN dated on 2017-12-18: Flexion Therapeutics Enrolls First Patient In ZILRETTA SHIP Phase 2 Study

Financial news for FLXN dated on 2017-12-13: Flexion Therapeutics Reports Purchase GeneQuine Biotherapeutics' Global Rights To GQ-203 For Upfront Payment Of \$2M, Plus Milestone Payments Up To \$8.7M

Financial news for FLXN dated on 2017-12-11: Flexion Therapeutics Names Scott Kelley CMO

Financial news for FLXN dated on 2017-12-07: Flexion Therapeutics Reports Enrollment Of First Patient In Phase 2 Pharmacokinetics, Safety Study Of ZILRETTA In Bilateral Osteoarthritis Of The Knee

Financial news for FLXN dated on 2017-12-07: Flexion Therapeutics Enrolls First Patient In Phase 2 ZILRETTA Study

Financial news for FLXN dated on 2017-11-06: Flexion Therapeutics Reports Q3 EPS \$(1.07) vs \$(0.98) Est.

Financial news for FLXN dated on 2017-10-11: Flexion Therapeutics Prices Offering Of 4.8M Shares At \$25.50/Share

Financial news for FLXN dated on 2017-10-10: Flexion Therapeutics Announces 4M Share Common Stock Offering

Financial news for FLXN dated on 2017-10-06: Flexion Shares Resume Trading up 16%

Financial news for FLXN dated on 2017-10-06: Flexion Therapeutics to Resume Trading at 3:20pm EDT

Financial news for FLXN dated on 2017-10-06: Flexion's Zilretta Label Includes Results from Data from a Diabetes Study

Financial news for FLXN dated on 2017-10-06: Flexion Therapeutics Announces FDA Approval of Zilretta for Osteoarthritis Knee Pain

Financial news for FLXN dated on 2017-10-06: Flexion Halted, News Pending

Financial news for FLXN dated on 2017-10-06: REMINDER: Flexion Has PDUFA Date For Zilretta Today

Financial news for FLXN dated on 2017-10-05: Watching Flexion, AxelRx, Agile Therapeutics Shares Premarket Thurs. Following Reuters Highlighting 'RBC sees 3 small-cap drugmakers as candidates for takeover'; Stocks Not Moving

Financial news for FLXN dated on 2017-09-22: NantKwest Appoints Flexion Therapeutics CFO To Its Board

Financial news for FLXN dated on 2017-08-24: Northland Securities Initiates Coverage On Flexion Therapeutics with Outperform Rating, Announces \$40.00 Price Target

Financial news for FLXN dated on 2017-08-08: Flexion Therapeutics Reports Q2 Loss/Share \$(0.91) vs. \$(0.82) Est.

Financial news for FLXN dated on 2017-05-23: Flexion Shares Spiking Higher As CEO Currently Speaking On CNBC About America's Opioid Crisis

Financial news for FLXN dated on 2017-05-04: Flexion Therapeutics Reports Q1 EPS \$(0.75) vs \$(0.72) Est.

Financial news for FLXN dated on 2017-04-07: Flexion Therapeutics Names Yamo Deniz Chief Medical Officer

Financial news for FLXN dated on 2017-04-04: Flexion Therapeutics Reports Issuance of 2 New Patents Further Strengthening Intellectual Property Protection (IP) for Zilretta

Financial news for FLXN dated on 2017-03-23: FiercePharma Says Sanofi On Verge Of \$1B-Plus Deal For Flexion According To Sources

Financial news for FLXN dated on 2017-03-09: Flexion Announces PDUFA Date Of Oct. 6, 2017 For Zilretta

Financial news for FLXN dated on 2017-03-09: Flexion Reports FY16 EPS \$(2.84) vs \$(2.75) Est.

Financial news for FLXN dated on 2017-02-23: Flexion Therapeutics Begins Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta

Financial news for FLXN dated on 2017-02-07: Flexion Therapeutics Announces New Drug

Application for Zilretta Accepted By FDA

Financial news for FLXN dated on 2016-12-22: Raymond James Initiates Coverage On Flexion Therapeutics at Strong Buy

Financial news for FLXN dated on 2016-09-06: Lake Street Assumes Flexion Therapeutics at Buy, Announces \$38.00 PT

Financial news for FLXN dated on 2016-06-29: BMO Capital Initiates Coverage on Flexion Therapeutics at Outperform

Financial news for FLXN dated on 2015-12-10: Earlier Janney Capital Assumed Flexion Therapeutics at Buy, Announces \$27.00 PT

Financial news for FLXN dated on 2015-03-30: MLV & Co Initiates Coverage on Flexion Therapeutics at Buy, Announces \$38.00 PT

Financial news for FLXN dated on 2015-02-16: RBC Capital Initiates Coverage on Flexion Therapeutics at Outperform, Announces \$37.00 PT

Financial news for FLXN dated on 2015-02-02: Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee

Financial news for FLXN dated on 2014-08-14: Summer Street Initiates Coverage on Flexion Therapeutics at Buy, Announces \$25.00 PT

Financial news for FLXN dated on 2014-08-07: Flexion Therapeutics Reports Q2 EPS of \$(0.38) vs \$(0.52) Est

Financial news for FLXN dated on 2014-05-08: Flexion Therapeutics Reports Q1 EPS of \$(0.86) vs \$(0.52) Est

Financial news for FLXN dated on 2014-03-27: Flexion Therapeutics Reports FY13 EPS of \$(23.02)

Financial news for FLXN dated on 2014-03-19: Janney Capital Initiates Coverage on Flexion Therapeutics at Buy, Announces \$25.00 PT

Financial news for FLXN dated on 2014-03-10: Needham Initiates Coverage on Flexion Therapeutics at Buy, Announces \$26.00 PT

Financial news for FLXN dated on 2014-03-10: BMO Capital Initiates Coverage on Flexion Therapeutics at Outperform, Announces \$33.00 PT

Financial news for FLXN dated on 2014-03-10: Wells Fargo Initiates Coverage on Flexion Therapeutics at Outperform

Financial news for FLXN dated on 2014-02-11: Flexion Therapeutics Prices 5M Share IPO at \$13.00/Share

Financial news for FLXN dated on 2014-01-08: Flexion Therapeutics Files \$86.25M IPO, Planning to List on NASDAQ Under 'FLXN'